Company intelligence / Profile preview
Shanghai Jiatan Pharmatech
- Ownership
- Private
- Development stage
- Phase 3
Overview
Shanghai Jiatan Pharmatech is a Chinese pharmaceutical company focused on developing small molecule therapeutics for infectious diseases such as tuberculosis and for oncology indications. Its lead TB drug WX‑081 is an oral adenosine triphosphatase inhibitor in Phase II/III trials for pulmonary tuberculosis. The company also has a PI3K-mTOR dual inhibitor (WX390/WXFL10030390) in clinical development for various cancers including STK11-mutant tumors and lymphomas. Early data show promising safety and antitumor activity.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Shanghai Jiatan Pharmatech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Jiatan Pharmatech.